Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3674112018 | Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3674113011 | Bendroflumethiazide 2.5 mg and potassium chloride 630 mg prolonged-release oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has manufactured dose form | Prolonged-release oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Is a | Potassium chloride-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator value | 630 | false | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Bendroflumethiazide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Bendroflumethiazide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator value | 2.5 | false | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Potassium chloride | true | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Potassium chloride | true | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Is a | Bendroflumethiazide-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Count of base of active ingredient | 2 | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Is a | Bendroflumethiazide and potassium chloride only product in oral dose form | true | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) | Plays role | Diuretic therapeutic role | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR